PharmaLinkFHI, a contract research organization based in the Triangle, is expanding its global footprint by acquiring Matrix Contract Research, a CRO based in the United Kingdom.

Financial terms of the deal were not disclosed.

The deal is part of PharmaLink’s strategy to expand its capabilities and reach, according to Chief Executive Officer Richard Staub.

“After several years of robust growth, it was critical for PharmaLink to expand its clinical reach and client service offerings and become a global company,” Staub said in a statement.

“The integration of Matrix with PharmaLink’s unique eClinical service delivery model will allow us jointly to better serve our clients who require development services throughout the North America, Western, Central, and Eastern Europe, including Russia,” he added.

The companies have worked together in the past on several projects, including global clinical trials and management.

By combining the two firms, PharmaLink plans to offer what it called “full service, turnkey global research services.”

Nigel Trim, who is president of Matrix, will lead European operations for the merged company.

PharmaLink manages Phase I-IV clinical trials and post-marketing programs. It is affiliated with Durham-based Family Health International, a health research and services firm that operates in more than 40 countries.